Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia

Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation

(2022) Wen Yao et al.   Mediterranean Journal of Hematology and Infectious Diseases

Targeting NAT10 Induces Apoptosis Associated With Enhancing Endoplasmic Reticulum Stress in Acute Myeloid Leukemia Cells

(2021) Jie Zi et al.   Frontiers in Oncology

Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia

(2021) Xuejie Jiang et al.   Journal of Translational Medicine

3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?

(2021) Kenny Tang et al.   Current Oncology Reports

JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles

(2021) Jaime A Castro-Mondragon et al.   NUCLEIC ACIDS RESEARCH

Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway

(2020) Jing Liu et al.   Translational Cancer Research

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia

(2020) Chunhua Song et al.   BLOOD

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

(2020) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma

(2020) Jonas Ecker et al.   NEURO-ONCOLOGY

Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway

(2020) Liman Lin et al.   Frontiers in Pharmacology

The Multifaceted Roles of RCC1 in Tumorigenesis

(2020) Xuanqi Ren et al.   Frontiers in Molecular Biosciences

Chronic myelomonocytic leukemia - a review

(2020) Thomas P. Thomopoulos et al.   Expert Review of Hematology

HDAC Inhibitors in Acute Myeloid Leukemia

(2019) San José-Enériz et al.   Cancers

Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels

(2019) He Huang et al.   Frontiers in Oncology

Cladribine: mechanisms and mysteries in multiple sclerosis

(2018) Benjamin Meir Jacobs et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy

(2017) Y. Lun et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

(2016) Angela Nebbioso et al.   CLINICAL CANCER RESEARCH

The ubiquitin ligase Huwe1 regulates the maintenance and lymphoid commitment of hematopoietic stem cells

(2016) Bryan King et al.   NATURE IMMUNOLOGY

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

(2015) Y. Shi et al.   ANNALS OF ONCOLOGY

Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?

(2014) Craig W. Freyer et al.   AMERICAN JOURNAL OF HEMATOLOGY

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

(2010) G M Marshall et al.   ONCOGENE